Q-linea AB (SE:QLINEA)
:QLINEA
QLINEA Stock Chart & Stats
kr29.00
>-kr0.01(-3.85%)
At close: 4:00 PM EST
kr29.00
>-kr0.01(-3.85%)
Day’s Range― - ―
52-Week Rangekr20.79 - kr74.06
Previous CloseN/A
Volume6.05M
Average Volume (3M)13.43K
Market Cap
kr435.72M
Enterprise Value-kr94.55M
Total Cash (Recent Filing)kr258.11M
Total Debt (Recent Filing)kr7.71M
Price to Earnings (P/E)―
Beta2.94
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.73
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr107.00M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue ModelA platform-plus-consumables model creates durable, recurring revenue once instruments are placed. High per-test consumable demand aligns incentives between instrument adoption and long-term volume, supporting predictable revenue growth and stronger lifetime customer value if clinical adoption and utilization scale.
Low Leverage Reduces Near-term Financing RiskVery modest debt and low debt-to-equity provide flexibility and lower near-term default risk, giving management time to commercialize products without immediate pressure from creditors. This supports multi-quarter execution on placements and consumable ramp before needing urgent refinancing.
Targeting High-value Clinical Need (sepsis/AST)Addressing rapid antibiotic susceptibility testing for sepsis targets a persistent, high-priority hospital need where faster results change care and reduce costs. Structural demand from hospitals and labs for faster AST supports durable market opportunity and potential stickiness for workflow-integrated platforms.
Bears Say
Heavy Cash Burn / Negative Cash GenerationConsistent and sizable negative operating and free cash flow indicate the business cannot self-fund growth today. Persistent cash burn raises the likelihood of future equity or debt financing, which can dilute shareholders or restrict strategic choices, and constrains investment in commercial scale-up.
Negative Gross Profit And Persistent LossesNegative gross margins signal weak unit economics or immaturity in commercial pricing and cost structure. Sustained large operating losses suggest the company has not yet achieved scalable, profitable volume; this undermines long-term margin sustainability and the ability to convert placements into profitable recurring revenue.
Unstable Capital Structure; Past Negative EquityA history of negative equity reflects prior financing stress and raises the risk that future cash shortfalls require dilutive capital or onerous terms. This instability reduces strategic optionality and increases execution risk during multi-quarter commercialization efforts, especially if revenues remain uneven.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr20.79 and its highest was kr74.06 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr435.72M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Apr 30, 2026 which is in 21 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Feb 04, 2026. The company reported -kr3.733 earnings per share for the quarter, missing the consensus estimate of N/A by -kr3.733.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -kr3.733 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.68%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Technical Analysis
Vicore Pharma Holding AB
―
Isofol Medical AB
―
Biovica International AB Class B
―
Doxa AB
―
Guard Therapeutics International AB
―